4-isobutyrylbenzoic acid | 32018-30-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-isobutyrylbenzoic acid
• 英文别名: 4-(2-methylpropanoyl)benzoic acid
• CAS: 32018-30-7
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: FLICZDVBYUMMAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-isobutyrylbenzoic acid 在 titanium(IV) isopropylate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 26.0h， 生成 N-[(5-ethylsulfonylpyridin-2-yl)methyl]-4-[2-methyl-1-[[4-(trifluoromethyl)cyclohexyl]methylamino]propyl]benzamide
  参考文献：
  名称：

  一类 6-(三氟甲基)-吡啶衍生物作为 RORγt 反向激动剂的 SAR 研究

  摘要：

  目的：发现新型有效的 RORγt 反向激动剂，用于治疗 Th17 细胞相关的自身免疫性疾病，如牛皮癣和类风湿性关节炎。背景：核受体视黄酸受体相关孤儿受体γt（RORγt）是免疫细胞中重要的转录因子。从功能上来说，RORγt在促进T辅助17细胞的分化和调节白细胞介素17等促炎因子的表达方面发挥着重要作用。因此，RORγt被认为是治疗自身免疫性疾病的一个有前景的靶点。目前，已有21种不同支架的RORγt反向激动剂进入临床试验。目的：为了发现新型有效的RORγt反向激动剂，设计并合成了一系列新型6-(三氟甲基)吡啶衍生物。方法：我们基于VTP-43742设计合成了一系列强效RORγt反向激动剂W1~W16。采用分子对接、分子动力学（MD）模拟和MM/GBSA研究了衍生物的构效关系（SAR）。结果：生物活性评价表明目标化合物具有较强的RORγt抑制活性。最活跃的化合物W14在荧光素酶报告基因测定中表现出低纳摩尔抑制活性（IC50

  DOI：

  10.2174/0115701808234886230921063622
• 作为产物：
  描述：

  (4-Isobutyryl-phenyl)-oxo-acetic acid methyl ester 在 氢氧化钾 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 以78%的产率得到4-isobutyrylbenzoic acid
  参考文献：
  名称：

  A study on the mechanism and scope of the radical-mediated oxidation of arylacetoacetates

  摘要：

  Arylacetoacetate 1a undergoes an oxidative degradation in the presence of K(t)BuO, THF, catalytic I-2 and O-2, to give keto ester 4 as major compound. Hydrolysis and decarboxylation of this intermediate led to the corresponding arylcarboxylic acid 3a in satisfactory overall yields. By experiments conducted in the presence of O-18(2), incorporation of atmosphere oxygen into the benzylic position of 4 was evidenced. Furthermore, spin-trap experiments showed that benzyl radical 7 was generated in the reaction medium, which supports its role as intermediate in the pathway leading to the observed oxidation products. A plausible mechanism for this process is presented. On the other hand, appropriate conditions for achieving the alkylation of these arylacetoacetates with no concomitant formation of oxidation side-products are reported. Finally, arylacetates suffer also this degradative oxidation process leading to the corresponding arylcarboxylic acids without isolation of the intermediate keto ester derivative.

  DOI：

  10.1016/0040-4020(95)00576-t

文献信息

• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
  申请人：DEVGEN NV

  公开号：WO2005082367A1

  公开（公告）日：2005-09-09

  The invention provides the use of a compound or a composition comprising said compound for inhibiting the activity of at least one kinase, other than ROCK kinase, in vitro or in vivo, pharmaceutical and/or veterinary compositions comprising such compounds, medical and veterinary uses of such compounds and the compounds themselves.

  该发明提供了一种化合物或含有该化合物的组合物用于抑制体外或体内至少一种激酶（除ROCK激酶外）的活性，包括这些化合物的药用和/或兽医学组合物，这些化合物的医药和兽医用途以及化合物本身。
• Kinase inhibitors
  申请人：Leysen Casimir Maria Dirk

  公开号：US20070191420A1

  公开（公告）日：2007-08-16

  The invention provides the use of a compound or a composition comprising said compound for inhibiting the activity of at least one kinase, other than ROCK kinase, in vitro or in vivo, pharmaceutical and/or veterinary compositions comprising such compounds, medical and veterinary uses of such compounds and the compounds themselves.

  本发明提供了使用一种化合物或含有该化合物的组合物来抑制体外或体内至少一种激酶的活性（ROCK激酶除外），以及含有该类化合物的药物和/或兽医组合物，该类化合物的医学和兽医用途以及化合物本身。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
  申请人：Chappell Mark Donald

  公开号：US20080319074A1

  公开（公告）日：2008-12-25

  The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明披露了式(I)的新型化合物或其药学上可接受的盐，其具有胰高血糖素受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一实施方案中，本发明披露了包含式(I)化合物的药物组合物，以及使用它们治疗糖尿病和其他胰高血糖素相关代谢紊乱等疾病的方法。
• 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
  申请人：Colandrea J. Vincent

  公开号：US20060252741A1

  公开（公告）日：2006-11-09

  The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖式(I)化合物，以及其药学上可接受的盐。该化合物用于治疗免疫介导的疾病和病况，如骨髓、器官和组织移植排斥。包括药物组合物和使用方法。